Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 6/20 | 0.39 |
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | CA9 | Q16790 | 6/20 | 0.39 |
| ▸ | CA4 | P22748 | 5/20 | 0.39 |
| ▸ | TTPA | P49638 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803122 | 0.90 | CA12 (0.35) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL2802221 | 0.86 | CA12 (0.38) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL2805288 | 0.78 | PTGS2 (0.38) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL10824841 | 0.77 | PTGS2 (0.43) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL9951921 | 0.76 | NAAA (0.52) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL2803226 | 0.76 | CA12 (0.39) | CA12CA1CA2CA9 | |
| SCHEMBL2803118 | 0.76 | CA12 (0.34) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL23036023 | 0.76 | CA12 (0.43) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL21105278 | 0.76 | ALDH1A1 (0.50) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL23036025 | 0.76 | CA12 (0.43) | PTGS2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539729-A4 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-02-20 | — | — | EP | claimed |
| US-7163958-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED INC. (US) | 2007-01-16 | — | — | US | claimed |
| EP-1539729-A2 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040024057-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications | NITROMED, INC. | 2004-02-05 | — | — | US | claimed |
| WO-2004004648-A2 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-8222277-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2012-07-17 | — | — | US | disclosed |
| US-7754772-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX, S.A. (FR) | 2010-07-13 | — | — | US | disclosed |
| EP-1539729-A4 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20050222243-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| EP-1539729-A2 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040024057-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications | NITROMED, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2004004648-A2 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024057-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications | NOS2, NOS1, NOS3 | PTGS2 7/4885CA12 2643/4885CA1 2617/4885 |
| US-20050222243-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NOS2, NOS1, NOS3 | PTGS2 7/4885CA12 3151/4885CA1 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.